SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD - News) today disclosed it has entered into an agreement that extends studies of the Aethlon Hemopurifier® with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) under a cooperative research and development agreement (CRADA). The Hemopurifier® is the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The device has been designed to enhance the benefit of antiviral drug regimens, and it provides a therapeutic option against infectious viruses not addressed by drug and vaccine therapies.
